Congenital Muscular Dystrophies: Toward Molecular Therapeutic Interventions
- 11 March 2010
- journal article
- review article
- Published by Springer Science and Business Media LLC in Current Neurology and Neuroscience Reports
- Vol. 10 (2), 83-91
- https://doi.org/10.1007/s11910-010-0092-8
Abstract
Congenital muscular dystrophies (CMDs) are a clinically and genetically heterogeneous group of neuromuscular disorders that typically present at birth or in early infancy with hypotonia, weakness, and histologic evidence of a dystrophic myopathy. CMD biochemical types include various abnormalities of α-dystroglycan O-mannosyl glycosylation as well as defects in integrin matrix receptors, the extracellular matrix proteins laminin-α2 and collagen VI, nuclear proteins such as lamin A/C, and a protein of the endoplasmic reticulum, selenoprotein N. Current therapies are directed mostly at supportive care; however, recent advances in biotechnology and increased knowledge of the pathophysiology underlying the various CMD types have helped identify potential therapeutic strategies directed at genetic, molecular, and biochemical pathways involved in these disorders. In this article, we review our current understanding of the molecular pathogenesis of several CMD types and how these mechanisms may be therapeutically targeted.Keywords
This publication has 63 references indexed in Scilit:
- Basal lamina strengthens cell membrane integrity via the laminin G domain-binding motif of α-dystroglycanProceedings of the National Academy of Sciences of the United States of America, 2009
- Laminin-111 protein therapy prevents muscle disease in the mdx mouse model for Duchenne muscular dystrophyProceedings of the National Academy of Sciences of the United States of America, 2009
- Pathology is alleviated by doxycycline in a laminin‐α2–null model of congenital muscular dystrophyAnnals of Neurology, 2009
- Diminished binding of mutated collagen VI to the extracellular matrix surrounding myocytesMuscle & Nerve, 2008
- Cyclosporin A corrects mitochondrial dysfunction and muscle apoptosis in patients with collagen VI myopathiesProceedings of the National Academy of Sciences of the United States of America, 2008
- The zebrafishcandyflossmutant implicates extracellular matrix adhesion failure in laminin α2-deficient congenital muscular dystrophyProceedings of the National Academy of Sciences of the United States of America, 2007
- Angiotensin II type 1 receptor blockade attenuates TGF-β–induced failure of muscle regeneration in multiple myopathic statesNature Medicine, 2007
- Mitochondrial dysfunction in the pathogenesis of Ullrich congenital muscular dystrophy and prospective therapy with cyclosporinsProceedings of the National Academy of Sciences of the United States of America, 2007
- Deletion of brain dystroglycan recapitulates aspects of congenital muscular dystrophyNature, 2002
- An agrin minigene rescues dystrophic symptoms in a mouse model for congenital muscular dystrophyNature, 2001